Synergy Chc Corp. (SNYRQ) Stock Forecast Nov. 6, 2026
Analysis updated on Nov. 6, 2026 (UTC) · Alpha · vs marketSwitch to Total · OTC
Synergy Chc Corp. (SNYRQ) stock forecast summary
Our AI scores Synergy Chc Corp. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Its market capitalization is not available, so no size classification is given.
A per-ticker accuracy statistic for SNYRQ is published only once its sample size is known. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +3.1%, buy ≥ +1.5%, sell < -0.5%, strong sell < -1.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-06 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, SNYRQ included.
SNYRQ price chart and AI forecast
How SNYRQ ranks among 5150 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Synergy Chc Corp. (SNYRQ) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Medicinal Chemicals & Botanical Products peers listed below that report each metric.
Valuation & Market
| Metric | SNYRQ | Rank |
|---|---|---|
| EPS | $-0.22 | – |
Profitability & Margins
| Metric | SNYRQ | Rank |
|---|---|---|
| ROA | -13.1% | 12/21 |
| Gross Margin | 74.4% | 2/21 |
| Operating Margin | 14.4% | 1/23 |
| Net Margin | -2.9% | 5/19 |
| EBT Margin | 0.2% | 8/23 |
| Tax Rate | 257.4% | – |
The effective tax rate is outside the normal band, which points to a large non-recurring tax item in the trailing twelve months; headline net income, net margin and P/E are affected by it.
Financial Health
| Metric | SNYRQ | Rank |
|---|---|---|
| Current Ratio | 0.93x | 18/25 |
| Quick Ratio | 0.43x | 16/23 |
| Working Capital | -$500K | 18/25 |
Cash Flow
| Metric | SNYRQ | Rank |
|---|---|---|
| Operating Cash Flow | -$5M | 20/27 |
Operational Efficiency
| Metric | SNYRQ | Rank |
|---|---|---|
| Inventory Turnover | 2.3x | 13/19 |
| Days Inventory | 159 days | 6/18 |
| Payables Period | 9 days | 17/17 |
Income Statement
| Metric | SNYRQ | Rank |
|---|---|---|
| Operating Income | $4M | 5/26 |
| Net Income | -$850K | 5/21 |
| SG&A Expense | $18M | 11/16 |
| Cost of Goods Sold | $8M | 15/22 |
Dividend & Shareholder Information
| Metric | SNYRQ | Rank |
|---|---|---|
| Net Income Growth | -125.9% | 3/5 |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $6M | |
| Cash & Short-term Investments | $290K | |
| Accounts Receivable | $1M | |
| Inventory | $3M | |
| Total Liabilities | $32M | |
| Short-term Debt | $7M |
SNYRQ quarterly financials and insider trading
Synergy Chc Corp. (SNYRQ) industry peers
Companies classified under the same SEC industry code as Synergy Chc Corp. (Medicinal Chemicals & Botanical Products): 30 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| SNYRQ Synergy Chc Corp. | N/A | |
| DFTX Definium Therapeutics, Inc. | $4.47B | |
| TRLV Trulieve Cannabis Corp. | $1.97B | |
| CRON Cronos Group Inc. | $1.33B | |
| TLRY Tilray Brands, Inc. | $432M | |
| SNDL Sndl Inc. | $355M | |
| ACB Aurora Cannabis Inc | $332M | |
| CGC Canopy Growth Corp | $276M | |
| USNA Usana Health Sciences Inc | $256M | |
| GLAS Glass House Brands Inc. | $196M | |
| MDWD Mediwound Ltd. | $171M | |
| NAGE Niagen Bioscience, Inc. | $164M | |
| AAWH Ascend Wellness Holdings, Inc. | $75M | |
| FTLF Fitlife Brands, Inc. | $75M | |
| CHUC Charlie's Holdings, Inc. | $31M | |
| BTMD Biote Corp. | $30M | |
| MRMD Marimed Inc. | $26M | |
| HYEX Healthy Extracts Inc. | $21M | |
| MTEX Mannatech Inc | $16M | |
| ADIA Adia Med, Inc. | $9M | |
| GLUC Glucose Health, Inc. | $9M | |
| BON Bon Natural Life Ltd | $7M | |
| NAII Natural Alternatives International Inc | $7M | |
| PLSH Panacea Life Sciences Holdings, Inc. | $6M | |
| AIBT Aibotics, Inc. | $3M | |
| CYAN Cyanotech Corp | $3M | |
| IMCC Im Cannabis Corp. | $980K | |
| NPHC Nutra Pharma Corp | $720K | |
| MEHA Functional Brands Inc. | $140K | |
| NTRR Neutra Corp. | N/A |
Where SNYRQ sits on the market map
Synergy Chc Corp. (SNYRQ) stock news
Loading...
Synergy Chc Corp. (SNYRQ) stock forecast FAQ
What is the Synergy Chc Corp. (SNYRQ) stock forecast?
Our AI scores Synergy Chc Corp. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
How accurate are Synergy Chc Corp. stock predictions?
A per-ticker accuracy statistic for SNYRQ is published only once its sample size is known. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Synergy Chc Corp. forecasts updated?
Synergy Chc Corp. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 6, 2026.
Which companies are Synergy Chc Corp.'s industry peers?
30 issuers in our coverage, SNYRQ included, share the SEC industry code Medicinal Chemicals & Botanical Products. The largest are: Definium Therapeutics, Inc. (DFTX), Trulieve Cannabis Corp. (TRLV), Cronos Group Inc. (CRON), Tilray Brands, Inc. (TLRY), Sndl Inc. (SNDL), Aurora Cannabis Inc (ACB).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.